Discovering new ways to make better drugs
The key to solving some of our world's biggest challenges, whether that be in medicine or agriculture, relies on the ability to precision engineer molecules at will. These could be new cancer drugs that harness the body's immune system or new antibiotics that are resistant resilient.
We aspire to harness three technological pillars in computational biology, molecular libraries, and nanotechnology to design better drugs.
Computational Biology
We use computational algorithms to predict drug properties with unprecedented accuracy
Molecular Biology
We use molecular libraries capable of screening through billions of drug leads to design drugs efficiently
Nanotechnology
Nano-sized reaction droplets to capture drug activity to make drugs that actually work
We will apply technological developments to peptides and proteins, molecules that are naturally able to bind targets with exquisite specificity.
Wang Group Team
Group leader
Dr Conan Wang
Group Leader, Technology-driven drug discovery
+61 7 334 62014
c.wang@imb.uq.edu.au
UQ Experts Profile
Computational design of targeted cancer therapeutics guided by machine learning
Principal advisor: Dr Conan Wang c.wang@imb.uq.edu.au
Opportunities are available to develop skills in drug discovery in computational biology and molecular biology. The aim is to accurately predict and quickly design new protein drugs to accelerate translation of new medicines. Please reach out if you would like to know more about drug design or potential projects.
Efficient design of drugs using new nanoscale technologies
Principal advisor: Dr Conan Wang c.wang@imb.uq.edu.au
Powerful technologies have emerged to perform millions of experiments quickly in tiny nanolitre droplets, and have attracted wide interest from major pharmaceutical companies because of the potential to accelerate drug discovery. Honours project opportunities are available to investigate these next-generation tools for drug design and learn new skills in one or more areas of nanotechnology and molecular biology.
Designing protein drugs for the treatment of cancer and inflammatory diseases
Principal advisor: Dr Conan Wang c.wang@imb.uq.edu.au
Cytokines are signalling proteins that play essential roles in immune responses and have garnered clinical interest in the context of cancer, autoimmunity, and infectious disease. This project aims to overcome their limitations of poor stability, activity, and specificity to develop new therapeutics. Candidates will learn new skills in drug design and characterisation using tools in molecular biology, biochemistry, and structural biology.
Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy.
Yin H, Zhou X, Huang YH, King GJ, Collins BM, Gao Y, Craik DJ, Wang CK.
J Am Chem Soc. 2021 Nov 10;143(44):18536-18547. doi: 10.1021/jacs.1c08132. Epub 2021 Oct 18.
PMID: 34661406
Improving Stability Enhances In Vivo Efficacy of a PCSK9 Inhibitory Peptide.
Zhang Y, Wang L, Tombling BJ, Lammi C, Huang YH, Li Y, Bartolomei M, Hong B, Craik DJ, Wang CK.
J Am Chem Soc. 2022 Oct 26;144(42):19485-19498. doi: 10.1021/jacs.2c08029. Epub 2022 Oct 12.
PMID: 36222719
Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.
Tombling BJ, Lammi C, Lawrence N, Gilding EK, Grazioso G, Craik DJ, Wang CK.
J Med Chem. 2021 Mar 11;64(5):2523-2533. doi: 10.1021/acs.jmedchem.0c01766. Epub 2020 Dec 23.
PMID: 33356222
Anchor Residues Guide Form and Function in Grafted Peptides.
Yin H, Craik DJ, Wang CK.
Angew Chem Int Ed Engl. 2019 Jun 3;58(23):7652-7656. doi: 10.1002/anie.201901572. Epub 2019 May 2.
PMID: 30916847
EGF-like and Other Disulfide-rich Microdomains as Therapeutic Scaffolds.
Tombling BJ, Wang CK, Craik DJ.
Angew Chem Int Ed Engl. 2020 Jul 6;59(28):11218-11232. doi: 10.1002/anie.201913809. Epub 2020 Mar 2.
PMID: 31867866
Designing macrocyclic disulfide-rich peptides for biotechnological applications.
Wang CK, Craik DJ.
Nat Chem Biol. 2018 May;14(5):417-427. doi: 10.1038/s41589-018-0039-y. Epub 2018 Apr 16.
PMID: 29662187
Our approach
We use computational biology, molecular libraries, and nanotechnology to design better drugs for human benefit.
Research areas
- cancer diagnostics and therapeutics
- immunology and inflammation
- antimicrobial agents
Latest news
-
-
Why are scientists so against daylight saving?
1 October 2024 -
Developing venom-based epilepsy drugs using lab-grown organs
25 September 2024
General enquiries
+61 7 3346 2222
imb@imb.uq.edu.au
Media enquiries
IMB fully supports UQ's Reconciliation Action Plan and is implementing actions within our institute.
Support us
Donate to research
100% of donations go to the cause